ERVW-1 and cancer: This biological duality—coexisting immunosuppression and targetable immunogenicity—positions HERVs as both predictive biomarkers and therapeutic targets, with current clinical trials exploring Env‐blocking antibodies and personalized vaccines to exploit these mechanisms for cancer immunotherapy.